The CDCN Annual Accelerating Research & Treatment for Castleman Disease Working Dinner at ASH
The Castleman Disease Collaborative Network (CDCN) hosted the 13th Annual “Accelerating Research & Treatment for Castleman Disease,” working dinner in-person on December 7, 2024 at the annual American Society of Hematology Meeting in San Diego, CA. We were joined with fellow physicians and researchers from around the globe, who are dedicated to advancing the understanding and treatment of Castleman disease. The in-person event discussed cutting edge research and important issues for patient care.
This annual gathering is a tremendous example of the power of the CDCN’s collaborative research approach to defeating Castleman disease.
CDCN Working Dinner Poster Session
| Submitted by |
Abstract Title |
| Kelly Makarounas-Kirchmann | Update on the development of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS) Abstract Link, Poster Link |
| Caroline Galeotti | Idiopathic multicentric Castleman disease associated with Duchenne dystrophy and cutaneous leukocytoclastic vasculitis in a 4-year-old child Abstract Link, Poster Link |
| Nicole Princic | Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis using a Health-Claims Dataset Abstract Link, Poster Link |
| Lu Zhang, MD | An Open-labeled Phase II Trial of VDJ-001, a High-Affinity IL-6R Antagonist Antibody, for the Treatment of Patients with Idiopathic Multicentric Castleman Disease Abstract Link, Poster Link |
| Steven Rowe, MD | Ferritin, CRP, and serum CD25 distinguish between HLH and TAFRO Abstract Link, Poster Link |
| Lu Zhang, MD | Asymptomatic multicentric Castleman disease: A potential early stage of idiopathic MCD Abstract Link, Poster Link |
| Lu Zhang, MD | Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single-centre, retrospective study Abstract Link, Poster Link |
| Ligen Liu | Efficacy and Safety of R-PAD regimen in Patients with Severe Idiopathic multicentric Castleman disease Castleman Disease: A Retrospective Case Series Abstract Link |
| Lu Zhang, MD | Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen benefits severe cases Abstract Link, Poster Link |
| Lu Zhang, MD | TAFRO syndrome without pathology supporting Castleman disease: treated as iMCD-TAFRO or a distinct disease entity? Abstract link, Poster Link |
| Vinodh Pillai MD PhD | Comprehensive Spatial and Single Cell Mapping of Castleman Disease Reveals Pathogenic Stromal Cells and Cytokine Pathways Abstract Link |
| Joshua D. Brandstadter, MD, PhD, MSc | Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes Poster Link |
| Melanie D. Mumau, PhD | Trafficking, not lymphoproliferation, promotes lymphadenopathy in idiopathic multicentric Castleman disease Poster Link |
| Michael V. Gonzalez, PhD | Lymph Node Transcriptomics in Idiopathic Multicentric Castleman Disease (iMCD) Identifies Pathogenic Mechanisms and Biomarkers Including Increased Clusterin Expression Poster Link |
| Mateo Sarmiento Bustamante | The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease Poster Link |
| Saishravan Shyamsundar | Variable Response Rates Across Chemotherapy Regimens for Idiopathic Multicentric Castleman Disease Poster Link |
| Danielle Leão C. Farias, MD, MsC, MBA | Artificial Intelligence-Based Algorithm for Diagnosing Idiopathic Multicentric Castleman’s Disease in a Lower-Middle Income Country Poster Link |